Indeed, no significant changes in intestinal flora were observed after one week of GLP-1R agonist therapy in T2DM subjects; however, during long-term use, there was a significant change in the structure and overall composition of the flora and a significant decrease in the abundance of intestinal microorganisms compared to those before drug administration [97]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.